VIA
RCUS icon

Vident Investment Advisory’s Arcus Biosciences RCUS Stock Holding History

Vident Investment Advisory’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,276
Closed -$425K – 1318
2023
Q1 		$425K Sell
23,276
-588
-2% -$11.2K 0.01% 829
2022
Q4 		$494K Sell
23,864
-5,289
-18% -$146K 0.02% 723
2022
Q3 		$759K Sell
29,153
-3,031
-9% -$80.2K 0.02% 670
2022
Q2 		$815K Buy
32,184
+3,059
+11% +$74.9K 0.02% 695
2022
Q1 		$919K Buy
29,125
+4,855
+20% +$163K 0.02% 722
2021
Q4 		$982K Sell
24,270
-34,311
-59% -$1.33M 0.03% 714
2021
Q3 		$2.04M Sell
58,581
-4,184
-7% -$130K 0.06% 399
2021
Q2 		$1.72M Buy
62,765
+7,621
+14% +$218K 0.05% 467
2021
Q1 		$1.55M Sell
55,144
-190
-0.3% -$6.61K 0.05% 482
2020
Q4 		$1.44M Buy
55,334
+10,356
+23% +$251K 0.06% 423
2020
Q3 		$771K Sell
44,978
-3,222
-7% -$72K 0.04% 558
2020
Q2 		$1.19M Buy
+48,200
New +$1.3M 0.06% 421
2018
Q4 		– Sell
-146,384
Closed -$2.04M – 892
2018
Q3 		$2.04M Sell
146,384
-9,755
-6% -$124K 0.08% 322
2018
Q2 		$1.91M Buy
+156,139
New +$2.45M 0.08% 327

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vident Investment Advisory's RCUS Position: Q2 2023 in Review

Vident Investment Advisory sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 23,276 shares — an estimated $425K sold.

Vident Investment Advisory first reported a position in RCUS in Q2 2018 and held it in 14 quarters. The position peaked at $2.04M in Q3 2021. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

  • Vident Investment Advisory reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 23,276 Arcus Biosciences shares in Q2 2023, an estimated $425K.
  • Vident Investment Advisory first reported a position in Arcus Biosciences in Q2 2018 and held it in 14 quarters.
  • Vident Investment Advisory's Arcus Biosciences position peaked at $2.04M in Q3 2021.
  • 181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.